ubmslateCN-logo-ubm

CN Mobile Logo

Search form

Topics:

Leukemia & Lymphoma

Leukemia & Lymphoma

Here we review the role of interim PET/CT in diffuse large B-cell lymphoma (DLBCL), and also explore the question of whether new approaches to quantitative assessment improve the prognostic value of interim PET scans in both Hodgkin lymphoma and DLBCL.

Presentation with musculoskeletal manifestations as the only symptom in pediatric B-cell acute lymphoblastic leukemia was significantly associated with diagnostic delay. However, this delay did not affect patient prognosis.

The use of minimal residual disease provided a more objective measure of induction failure in patients with pediatric acute lymphoblastic leukemia than did morphology.

A small preliminary study showed that adding pioglitazone to imatinib therapy might have a favorable impact on residual disease in chronic myeloid leukemia, as measured by conversion to molecular response 4.5.

Complete response at 30 months (CR30) may be a useful surrogate endpoint for progression-free survival in trials of first-line follicular lymphoma treatments.

Patients with CML who have higher proportions of natural killer immune cells, and more mature natural killer cells, fare better when discontinuing therapy with imatinib.

Pages

Subscribe to Leukemia & Lymphoma on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.